<div id="readability-page-1">Viking Therapeutics Inc ( VKTX ) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from wider excitement in the obesity treatment area, as well as recent positive momentum after major clinical trial developments. <ul> <li>VKTX stock is racing ahead of the pack. Review the technical setup here.</li> </ul> What To Know: Viking shares have experienced volatility in recent weeks, but appear to be rebounding amid broader investor interest in GLP-1 and obesity drug developers. Viking disclosed toward the end of November that it had completed the patient enrollment for subcutaneous VK2735 in its Phase 3 VANQUISH-1 clinical trial ahead of schedule, which was a positive surprise for investors. The firm was able to attract nearly 4,650 adults who were either obese or overweight and impacted by at least one condition associated with their weight, which was larger than the target set for the trial. The rapid accrual of patients and the exceeding of the enrollment expectation were described by CEO Brian Lian as indicative of the patients’ “enthusiasm for new obesity treatments beyond those currently available.” The broader obesity drug market is experiencing significant momentum, with healthcare ETFs quietly benefiting from the $150 billion obesity-drug boom. As Eli Lilly And Co ( LLY ) and Novo Nordisk A/S ( NVO ) compete for dominance in the fast-growing GLP-1 market, investors are increasingly piling into diversified exposure through healthcare-focused funds. Eli Lilly ( LLY ) shares are up about 36% over the past three months. Eli Lilly ( LLY ) reported adjusted earnings of $7.02 per share for the third quarter, topping expectations and prompting the company to raise its full-year outlook. Meanwhile, Novo Nordisk ( NVO ) made a $6.5 billion counterbid for U.S. biotech Metsera, whose weight-loss research includes a longer-interval injection. The intensifying competition underscores just how high the stakes are in the GLP-1 market — and it's drawing additional investor attention to emerging players like Viking Therapeutics ( VKTX ). Viking is currently participating in the Piper Sandler 37th Annual Healthcare Conference that wraps up on Thursday in New York City. Company executives are taking part in a fireside chat expected to inform investors on the latest developments in the clinical area. <h3>VKTX Analysis</h3> Viking Therapeutics ( VKTX ) is currently showing strong short-term momentum, trading 6.4% above its 20-day SMA and 31.5% above its 200-day SMA. This positioning indicates a bullish trend, especially with the stock recently breaking above resistance at $39.50. The RSI is currently at 49.80, which is neutral, suggesting that the stock is neither overbought nor oversold at this moment. The MACD is below the signal line so traders should watch for potential shifts if the stock approaches key support at $34.00 or resistance at $39.50. Looking at the three-month performance, VKTX has gained 53.61%, reflecting significant upward momentum. However, the 12-month trend tells a different story, with a decline of 23.61%, suggesting that VKTX has experienced volatility and may be recovering from a more significant downturn. This contrast between short-term gains and longer-term losses highlights the importance of monitoring the stock’s performance closely. Currently, VKTX is closer to its 52-week highs than its lows. This positioning can be a double-edged sword; while it suggests strength, it also means that traders should be cautious of potential pullbacks if the stock fails to maintain upward momentum. VKTX Price Action: Viking Therapeutics ( VKTX ) shares were up 11.17% at $35.29 at the time of publication on Thursday, according to Benzinga Pro. Read Next: <ul> <li>Behind the Scenes of Eli Lilly’s Latest Options Trends</li> </ul> Image: Shutterstock</div>

礼来

诺和诺德公司

Viking治疗

Viking Therapeutics (VKTX) 的股价因对肥胖治疗的兴奋和积极的临床试验进展上涨了 11.17%。该公司提前完成了其第三阶段 VANQUISH-1 试验的患者招募，吸引了比预期更多的参与者。这一势头是对 GLP-1 和肥胖药物开发者更广泛兴趣的一部分，礼来和诺和诺德等主要参与者在市场上竞争。VKTX 显示出强劲的短期动能，交易价格高于其 20 日和 200 日简单移动平均线，表明看涨趋势

Viking 治疗公司股票的跳涨是怎么回事？